Tharimmune Inc.
Investor Relations


Our Company Overview

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3.

Press Releases

Latest Financial Results

Q1 2024 – QUERTER ENDED MAR 31, 2024


Sign Up For Latest
News and Press Releases

Receive updates straight into your inbox